Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Johnson &amp; Johnson's single shot Covid vaccine could be offered by hospitals in India early as July as&nbsp;Association of Private Healthcare Providers in India (AHPI)&nbsp;is finalising import details with J&amp;J currently.
The J&amp;J vaccine's biggest advantage is that it has to be administered only once and is easy to store as well. As per data from the CDC&nbsp;it has a 66.3% efficacy.&nbsp;
J&amp;J has offered this single-shot vaccine at $25 (approximately ₹1,875) per dose, which AHPI is negotiating. Private hospitals are charging ₹ 780 per dose of Covishield, ₹ 1,410 per dose of Covaxin and ₹ 1,145 per dose of Sputnik
&nbsp;

Johnson & Johnson's single shot Covid vaccine likely to be in India as early as July

Johnson &amp; Johnson's single shot Covid vaccine likely to be in India as early as July

Vaccine choice set to increase

Johnson &amp; Johnson's single shot Covid vaccine likely to be in India as early as July

<ul>
<li>Private hospitals finalising deal with J&amp;J for importing vaccine</li>
<li>&nbsp;Association of Private Healthcare Providers in India to procure vaccines directly from J&amp;J</li>
<li>J&amp;J vaccine likely to be priced at ₹ 1875/dose in private hospitals&nbsp;</li>
</ul>

Johnson &amp; Johnson's single shot Covid vaccine could be offered by hospitals in India early as July as&nbsp;Association of Private Healthcare Providers in India (AHPI)&nbsp;is finalising import details with J&amp;J currently.
The J&amp;J vaccine's biggest advantage is that it has to be administered only once and is easy to store as well. As per data from the CDC&nbsp;it has a 66.3% efficacy.&nbsp;
J&amp;J has offered this single-shot vaccine at $25 (approximately ₹1,875) per dose, which AHPI is negotiating. Private hospitals are charging ₹ 780 per dose of Covishield, ₹ 1,410 per dose of Covaxin and ₹ 1,145 per dose of Sputnik
&nbsp;

The UK drug regulator on Friday approved the use of the Johnson &amp; Johnson single-dose Covid-19 vaccine for use.&nbsp;The Johnson &amp; Johnson vaccine is the fourth vaccine to be used in the UK to protect against Covid-19 and order for twenty million doses have been placed, which will be delivered later this year.
Earlier in April, the European Medicines Agency had said that a warning about unusual blood clots with low blood platelet count should be added to the J&amp;J product information following cases in the United States.&nbsp;The vaccine was found to be 72% effective in preventing moderate to severe coronavirus infections, according to a US trial.

UK approves single shot Johnson & Johnson Covid vaccine

The UK drug regulator on Friday approved the use of the Johnson &amp; Johnson single-dose Covid-19 vaccine for use.&nbsp;The Johnson &amp; Johnson vaccine is the fourth vaccine to be used in the UK to protect against Covid-19 and order for twenty million doses have been placed, which will be delivered later this year.
Earlier in April, the European Medicines Agency had said that a warning about unusual blood clots with low blood platelet count should be added to the J&amp;J product information following cases in the United States.&nbsp;The vaccine was found to be 72% effective in preventing moderate to severe coronavirus infections, according to a US trial.

single dose vaccine

Categories